Lets take a look at the downsides
According to the group of authors, these polyagonists are in all likelihood the next step towards a cure for diabetes and obesity. Comparable to bariatric surgery The authors report on various polyagonists that are currently being researched in clinical studies and show improved efficacy with each new generation. The latest triple agonists attack both the glucose-dependent insulinotropic peptide receptor (GIPR) and the receptors for glucagon-like peptide 1 (GLP1) and glucagon (GCG, a hormone from the pancreas)
pp 125138 Fraschini F, Esposti D, Demartini G, Scaglione F, Lucini V, Mariani et al
10.2337/diabetes.47.4.530 117 ThorensB
Interestingly, interventions that boost NAD + levels resulted in extended lifespan in worms and mice 108,109,111,247 , suggesting a therapeutic potential for raising NAD + in various pathological conditions or age-associated diseases
Our main considerations included: How simple the onboarding experience is The clarity and ease of the sign-up process Wait times for medical review and prescriptions Quality and availability of follow-up support Cost Transparency And Insurance Support While GLP-1 medications may offer meaningful benefits, they often come at a high price
